Fig. 6

Tumoral c-Jun induces chemotherapy resistance of gemcitabine in PDAC. AThe representative bright field images of PDOs treated with GEM (400 nM, 72 h) were shown (left).The IC50 values of gemcitabine in each PDO were analysed by CellTiterGlo-3D assay (right). B Spearman correlation analysis between c-Jun expression and the IC50 of PDOs. C PDO6#-scramble/c-Jun-KD and PDO4#-vector/c-Jun-OE were treated with gemcitabine. The representative bright field images of organoids treated with GEM (400 nM, 72 h) (C, left). The IC50 value of gemcitabine in PDO6#-scramble/c-Jun-KD and PDO4#-vector/c-Jun-OE was analysed by CellTiterGlo-3D assay (C, right). D The representative images of apoptotic organoids by caspase3/7 probe labelled were shown and the percentage of apoptotic organoid cells were analysed in Fig. S10F. E The experimental design for in vivo PDOX assay. F-G Tumor volumes of PDOX were monitored by MRI scan. Representative MRI images per group at day 30 were shown (F) and tumor volumes were calculated by MRI scan (n = 6 per group, G). H Representative pancreatic tumor images per group at the experimental ending were shown (left) and tumor weight was determined (right). I Kaplan–Meier survival curves with log-rank test were used to analyze the effects after drug treatment in another cohort (n = 6). J-K The apoptotic and proliferative level of PDOX tumor in mice were evaluated by TUNEL staining (J) and Ki67 staining (K). All experiments were repeated three times independently. Paired Student’s t-test were used for in vitro experiments. Un-paired Student’s t-test were used for in vivo experiments